I don't remember hearing it that way, but if they are even working to achieve that, Sawston could be inspected by the FDA and others for commercial approval if requirements with blood products can be made out of country. I'm unsure if the US law currently allows it.
They are at 50/month capacity now. The theoretical limit is the ability to scale to 1000/month per the presentation but I guarantee that is far out. There is no autologous therapy that has reached the demand or ability to meet that demand yet.